| 摘要: |
| 舒尼替尼,是一种小分子多靶点酪氨酸激酶抑制剂(tyrosine kinase inhibitors, TKIs),广泛用于进展期肾细胞癌、胰腺神经内分泌瘤和胃肠道间质瘤的治疗。临床疗效显著,但存在严重的心脏毒性。具体表现为QT 间期延长(QT interval prolongation, QTIP)、左心室射血分数(left ventricular ejection fraction, LVEF)降低和心力衰竭(heart failure, HF),甚至心源性猝死；目前,舒尼替尼相关心脏毒性的确切机制尚未阐明,并且缺乏以证据为基础的防治手段。因此,深入了解舒尼替尼相关心脏毒性的特点、机制和防治措施显得尤为关键。本文就舒尼替尼相关心脏毒性的最新研究展开综述,以期为解决临床实际问题提供参考。 |
| 关键词: 舒尼替尼 心脏毒性 机制 防治 |
| DOI： |
| 分类号: |
| 基金项目: |
|
| Research progress on sunitinib-associated cardiotoxicity |
|
qin
|
|
Shanghai University of Traditional Chinese Medicine
|
| Abstract: |
| Sunitinib is widely used to treat solid tumors such as advanced renal cell carcinoma, pancreatic neuroendocrine tumors, and gastrointestinal mesenchymal tumors, but can lead to cardiotoxicity. The clinical manifestations are as follows: QT interval prolongation (QTIP), reduced left ventricular ejection fraction (LVEF), heart failure (HF), and even sudden cardiac death. Currently, the exact mechanism of sunitinib-related cardiotoxicity has not been elucidated, and there is still a lack of effective treatment for sunitinib-associated cardiotoxicity. Thus, it is important to understand the characteristics, mechanisms, and prevention measures of sunitinib-associated cardiotoxicity. The present review provides information on sunitinib-associated cardiotoxicity, with the aim of providing a reference for solving clinical problems. |
| Key words: Sunitinib, cardiotoxicity, mechanism, treatment |
